AstraZeneca Plc has bought $25 million worth of shares in Regulus Therapeutics Inc in parallel with that company’s initial public offering on the Nasdaq over-the-counter market. Regulus is developing therapies targeting microRNAs, short ribonucleic acid molecules.
